Rib-X raises $20M to support development of broad spectrum antibiotics pipeline

Rib-X Pharmaceuticals, Inc. today announced that the Company has raised $20 million to support ongoing development of the Company's industry-leading broad spectrum antibiotics pipeline, including late-stage clinical development of delafloxacin, which is expected to enter a Phase 2b study in early 2011.

“We are pleased to continue to support the Rib-X management team and the Company's innovative antibiotic pipeline, which targets infections resistant to existing antibiotics”

"2011 will be a transformational year for Rib-X and these funds will directly support a number of key initiatives for the Company," said Mark Leuchtenberger, President and Chief Executive Officer at Rib-X. "In early 2011, we will begin a Phase 2b delafloxacin study to validate new objective endpoints for a near-term Phase 3 study and will initiate a long-term preclinical safety study with radezolid to demonstrate its key points of differentiation. We also expect to nominate an initial development candidate with activity against multi-drug resistant Gram-negative bacteria from our Rχ-04 program in early 2011. We are grateful for the confidence and continued strong financial support of our investors and look forward to being able to deliver on the clinical promise of our pipeline."

The financing was led by current investor Warburg Pincus LLC. "We are pleased to continue to support the Rib-X management team and the Company's innovative antibiotic pipeline, which targets infections resistant to existing antibiotics," said Jonathan Leff, Managing Director at Warburg Pincus. "Through its deep expertise in antibiotics and insights in structure-based drug design around the bacterial ribosome, Rib-X has brought two differentiated products into advanced clinical development and has created a novel antibiotic discovery platform with the capability to target even the most resistant Gram-negative infections."

The Company's pipeline includes:

  • Delafloxacin, an empiric first line, hospital focused novel fluoroquinolone antibiotic that offers both IV and oral versatility in the treatment of resistant infections;
  • Radezolid, a next generation oxazolidinone antibiotic designed to be safer, have a broader spectrum of coverage and increased activity against Gram-positive organisms as compared to other oxazolidinones; and
  • Rχ-04, the broadest spectrum novel class of antibiotics active against serious, rapidly emerging multi-drug resistant bacteria, including Gram-negative bacteria.
Source:

 Rib-X Pharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Over-the-counter nasal sprays cut respiratory infections by 20%, study finds